The current wholesale acquisition cost (WAC) of pembrolizumab is $11,115 per dose. The WAC of toripalimab, recently approved for nasopharyngeal carcinoma, is 80% of pembrolizumab. In this simulation we modeled the cost-efficiency of the toripalimab regimen versus pembrolizumab in nsNSCLC and ...
The incremental costs and QALYs were then used to estimate the incremental cost-effectiveness ratio (ICER; incremental cost per QALY gained). We used an annual discount rate of 3% to determine the present value of costs and health outcomes in this economic evaluation. We depicted one-way ...
帕博利珠单抗生物类似药(Amgen): 一种PD-1抑制剂药物,由Amgen, Inc. (Amgen, Inc.)公司最早进行研发,目前全球最高研发状态为临床3期,作用机制: PD-1抑制剂(细胞程序性死亡-1抑制剂),治疗领域: 肿瘤,呼吸系统疾病,在研适应症: 非鳞状非小细胞肺癌,在研机构: Amgen, Inc
ALT or AST ≥3x ULN but <10x ULN with concurrent total bilirubin ≥2x ULN: Withhold both drugs and consider rechallenge with a single drug or sequential rechallenge with both drugs after recovery; if rechallenging with axitinib, consider dose reduction as per axitinib prescribing information ...
a dose of 2 mg/kg every three weeks. The primary efficacy outcome measure was ORR as assessed by Blinded Independent Central Review (BICR) using RECIST 1.1. Secondary efficacy outcome measures were duration of response (DOR) and progression-free survival (PFS; as assessed by B...
Patients received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (4.5%) of patients. Of the patients who developed pneumoni...
The following dosing strategies were evaluated using simulations: body weight, dose banding, fixed dose and pharmacokinetics based method. The relative cost to body weight dosing for band, fixed 150 mg and 200 mg, and pharmacokinetics derived strategies were -15%, -25%, +7% and -16% for ...
Similarly, ECOG 1684 showed that high-dose IFN alfa-2b prolongs relapse-free survival and OS in patients with high-risk resected melanoma.17 OS was 3.8 years, and it is conceivable that PD-1 axis blockade may potentiate this treatment's effects. Indeed, since adjuvant high-dose IFN alfa-2b...
In accordance with RECIST 1.1, we selected up to two target lesions per organ and a maximum of five in total. We summed up the target lesions diameters to obtain the SOD at each tumor size assessment for every patient. At each time of clinical tumor size evaluation we assigned to the ...
Patients received high-dose corticosteroids for a median duration of 10 days (range: 1 day to 2.3 months). Pneumonitis led to discontinuation of KEYTRUDA in 26 (4.5%) of patients. Of the patients who developed pneumonitis...